5 October 2022

Diaceutics PLC

("Diaceutics" or "the Company")

Purchase of Shares and PDMR Shareholding

Diaceutics PLC, (AIM: DXRX), a leading diagnostic commercialisation company which provides data, analytics and technology enabled services via its proprietary DXRX platform to the precision medicine market, announces that on 4 October 2022, Deborah Davis, the Chair of Diaceutics, purchased 21,200 ordinary shares of £0.002 each in the Company ("Ordinary Shares") at a price of 81 pence per Ordinary Share. As a result of the purchase, Deborah's shareholding is 86,000 Ordinary Shares, representing approximately 0.10% of the Company's issued share capital.

Enquiries:

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

Diaceutics' data capability is one of the three key value drivers it has integrated into its unique DXRX platform alongside its global Lab network and product suite tailored for Precision testing.